Skip to main content

View full-text article in PMC

. 2012 Nov 20;6:381–393. doi: 10.4137/CMO.S7350

Table 5.

Molecular targeted therapy of PNETs.

Design	Treatment	n	RR	Median PFS	Reference
Phase II	Sunitinib	66	17%	81% (1-year survival)	Kulke et al; J Clin Oncol 2008
Phase III	Sunitinib	86	9%	11.4 mo.^** vs. 5.5 mo.	Raymond et al; NEJM 2011
Phase III	Placebo	85	0%	11.4 mo.^** vs. 5.5 mo.	Raymond et al; NEJM 2011
Phase II (NR)	Everolimus	115	9.6%	9.6 mo.	Yao et al; JCO 2010
Phase II (NR)	Everolimus + octreotide LAR	45	4.4%	16.7 mo.	Yao et al; JCO 2010
Phase II	Everolimus + octreotide LAR	30	27%	12.5 mo.	Yao et al; JCO 2008
Phase III	Everolimus	207	5%	11 mo.^** vs. 4.6 mo.	Yao et al; NEJM 2011
Phase III	Placebo	203	2%	11 mo.^** vs. 4.6 mo.	Yao et al; NEJM 2011
Phase II	Temsirolimus	15	6.7%	10.6 (TTP)	Duran et al; Br J Cancer 2006
Phase II	Sorafenib	43	10%	61% (6-mo.)	Hobday et al; JCO 2007
Phase II	Pazopanib	17	7.1%⁺	10.0 mo.⁺	Grande et al; ESMO 2012
Phase II	Pazopanib + octreotide LAR	29	17%	11.7 mo.	Phan et al; JCO 2010

Notes:

^*

P < 0.05;

^**

P < 0.01;

⁺

including 25 non-PNETs.

Abbreviations: PFS, progression free survival; NR, non-randomized; TTP, time to tumor progression.